The University of British Columbia

British Columbia Cancer Agency Branch

Provincial Health Services Authority

Columbia University

Jun Wang

Raymond John Andersen

Marianne Dorothy Sadar

Nasrin R Mawji

Carmen Adriana Banuelos

David Williams

Mike Leblanc

Kunzhong Jian

Javier Garcia Fernandez

Yu-Chi Yang

Lu-Ping Yan

Yusuke Imamura

Jian Kunzhong

Amy (Hsing Chen) Tien

David E Williams

Nasrin R Mawjl

Kunzhong Jlan

Hsing Chen Tien

Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R, R, R, R, R, R, R, and X, are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.

Bisphenol derivatives and their use as androgen receptor activity modulators

Compounds having a structure of Formula I or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R, R, R, R, R, R, R, and X, are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.

This invention provides compound having a structure of Formula I or Formula II. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided. 

Diglycidic ether derivative therapeutics and methods for their use

Compounds having a structure of Formula (A) are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are provided. Uses of compounds having a structure of Formula (F) for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.

Small molecule inhibitors of N-terminus activation of the androgen receptor

Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R, R, R, R, R, X, X, Xand Xare as defined herein, and wherein the compound comprises at least one F, Cl, Br, I orI moiety, are provided. Uses of such compounds for imaging diagnostics in cancer and therapeutics methods for treatment of subjects in need thereof, including prostate cancer as well as methods and intermediates for preparing such compounds are also provided.

Halogenated compounds for cancer imaging and treatment and methods for their use

Compounds having a structure of Structure I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R, R, R, R, R, J, J, X, Z, nand nare as defined herein, and wherein at least one of R, Ror Ris an alkyl, alkenyl, aryl or aralkyl ester, are provided. Uses of such compounds for treatment of various indications, including prostate cancer, as well as methods of treatment involving such compounds are also provided.

Ester derivatives of androgen receptor modulators and methods for their use

This invention provides compound having a structure of Formula I or Formula II  Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.

Growing community of inventors

New Westminster, Canada

Jun Wang